Cerebralcare Granule attenuates cognitive impairment in rats continuously overexpressing microRNA-30e

Molecular Medicine Reports

Volumn 12, Issue 6, 2015, Pages 8032-8040

  Xu, Yong ^a   Liu, Zhifen ^a   Song, Xi ^a   Zhang, Kerang ^a   Li, Xingrong ^a   Li, Jianhong ^a   Yan, Xu ^a,b   Li, Yuan ^b   Xie, Zhongchen ^c   Zhang, Hui ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Cerebralcare Granule; Cognitive impairment; MicroRNA 30e; Neuropsychiatric disorders; Overexpression

Indexed keywords

CEREBRALCARE GRANULE; CHINESE DRUG; MICRORNA; MICRORNA 30E; PROTEIN BCL 2; PROTEIN UBC9; UNCLASSIFIED DRUG; CEREBRALCARE PREPARATION; HERBACEOUS AGENT; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN-CONJUGATING ENZYME UBC9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; APOPTOSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; HIPPOCAMPUS; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; INVESTIGATIVE PROCEDURES; MALE; MORRIS WATER MAZE TEST; NONHUMAN; OPEN FIELD TEST; PROTEIN EXPRESSION; RAT; REFERENCE MEMORY; SCHIZOPHRENIA; TUNEL ASSAY; WESTERN BLOTTING; WORKING MEMORY; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MAZE TEST; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; COGNITION DISORDERS; DENTATE GYRUS; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84946780890     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4469     Document Type: Article

References (57)

1. Caspi A and Moffitt TE: Gene-environment interactions in psychiatry: Joining forces with neuroscience. Nat Rev Neurosci 7: 583-590, 2006.
2. Tsuang MT, Bar JL, Stone WS and Faraone SV: Gene-environment interactions in mental disorders. World Psychiatry 3: 73-83, 2004.
3. Cross-Disorder Group of the Psychiatric Genomics Consortium: Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381: 1371-1379, 2013.
4. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
6. Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349, 2004.
7. Martinez NJ and Gregory RI: MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. Cell Stem Cell 7: 31-35, 2010.
8. Olde Loohuis NF, Kos A, Martens GJ, Van Bokhoven H, Nadif Kasri N and Aschrafi A: MicroRNA networks direct neuronal development and plasticity. Cell Mol Life Sci 69: 89-102, 2012.
9. Bravo JA and Dinan TG: MicroRNAs: A novel therapeutic target for schizophrenia. Curr Pharm Des 17: 176-188, 2011.
10. Dwivedi Y: Evidence demonstrating role of microRNAs in the etiopathology of major depression. J Chem Neuroanat 42: 142-156, 2011.
11. Forero DA, van der Ven K, Callaerts P and Del-Favero J: miRNA genes and the brain: Implications for psychiatric disorders. Hum Mutat 31: 1195-1204, 2010.
12. Hunsberger JG, Austin DR, Chen G and Manji HK: MicroRNAs in mental health: From biological underpinnings to potential therapies. Neuromolecular Med 11: 173-182, 2009.
13. Miller BH and Wahlestedt C: MicroRNA dysregulation in psychiatric disease. Brain Res 1338: 89-99, 2010.
14. Siew WH, Tan KL, Babaei MA, Cheah PS and Ling KH: MicroRNAs and intellectual disability (ID) in Down syndrome, X-linked ID, and Fragile X syndrome. Front Cell Neurosci 7: 41, 2013.
15. Brinton RD: Estrogen-induced plasticity from cells to circuits: Predictions for cognitive function. Trends Pharmacol Sci 30: 212-222, 2009.
16. Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C and Gulinello M: A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3. 1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front Neurosci 9: 279, 2015.
17. Perri R, Nares S, Zhang S, Barros SP and Offenbacher S: MicroRNA modulation in obesity and periodontitis. J Dent Res 91: 33-38, 2012.
18. Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 81: 388-396, 2013.
19. Xu Y, Li F, Zhang B, Zhang K, Zhang F, Huang X, Sun N, Ren Y, Sui M and Liu P: MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr Res 119: 219-227, 2010.
20. Liao Y and Lönnerdal B: Beta-catenin/TCF4 transactivates miR-30e during intestinal cell differentiation. Cell Mol Life Sci 67: 2969-2978, 2010.
21. Wu F, Zhu S, Ding Y, Beck WT and Mo YY: MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15: 1550-1557, 2009.
22. Wang J Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, Ma Z, Dai C, Li X, et al:. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. Cell Death Dis 4:e845,2013.
23. Khanna A, Muthusamy S, Liang R, Sarojini H and Wang E: Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice. Aging (Albany NY) 3: 223-236, 2011.
24. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA and Cairns MJ: Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 17: 827-840, 2012.
25. Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E and Akbarian S: Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 65: 1006-1014, 2009.
26. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J and Hammond SM: microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8: R27, 2007.
27. Rege SD, Geetha T, Pondugula SR, Zizza CA, Wernette CM and Babu JR: Noncoding RNAs in neurodegenerative diseases. ISRN Neurol 2013: 375852, 2013.
28. Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, Schmitt A, Schneider A, Cabral H, Cagsal-Getkin O, et al: Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One 8: e48814, 2013.
29. Xu XS, Ma ZZ, Wang F, Hu BH, Wang CS, Liu YY, Zhao XR, An LH, Chang X, Liao FL, et al: The antioxidant Cerebralcare Granule attenuates cerebral microcirculatory disturbance during ischemia-reperfusion injury. Shock 32: 201-209, 2009.
30. Wang F, Hu Q, Chen CH, Xu XS, Zhou CM, Zhao YF, Hu BH, Chang X, Huang P, Yang L, et al: The protective effect of Cerebralcare Granule on brain edema, cerebral microcirculatory disturbance, and neuron injury in a focal cerebral ischemia rat model. Microcirculation 19: 260-272, 2012.
31. Huang P, Zhou CM, Qin-Hu, Liu YY, Hu BH, Chang X, Zhao XR, Xu XS, Li Q, Wei XH, et al: Cerebralcare Granule attenuates blood-brain barrier disruption after middle cerebral artery occlusion in rats. Exp Neurol 237: 453-463, 2012.
32. Sun K, Hu Q, Zhou CM, Xu XS, Wang F, Hu BH, Zhao XY, Chang X, Chen CH, Huang P, et al: Cerebralcare Granule, a Chinese herb compound preparation, improves cerebral microcirculatory disorder and hippocampal CA1 neuron injury in gerbils after ischemia-reperfusion. J Ethnopharmacol 130: 398-406, 2010.
33. Xiong L, Zhang JJ, Sun D and Liu H: Therapeutic benefit of Yangxue Qingnao Granule on cognitive impairment induced by chronic cerebral hypoperfusion in rats. Chin J Integr Med 17: 134-140, 2011.
34. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L and Lowenstein PR: Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther 16: 741-751, 2005.
35. Miyoshi H, Blömer U, Takahashi M, Gage FH and Verma IM: Development of a self-inactivating lentivirus vector. J Virol 72: 8150-8157, 1998.
36. Naldini L, Blömer U, Gage FH, Trono D and Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93: 11382-11388, 1996.
37. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L and Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880, 1998.
38. Rattiner LM, Davis M, French CT and Ressler KJ. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci 24 4796-4806, 2004
39. Heldt SA, Stanek L, Chhatwal JP and Ressler KJ: Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12: 656-670, 2007.
40. Chenghong, Zoology experimental guidance. Tsinghua University 978-7-302-10763-7, 2005.
41. Paxinos G and Franklin KBJ: The mouse brain in stereotaxic coordinates. San Diego: Academic Press, 2001.
42. Morris RGM: Spatial localization does not require the presence of local cues. Learn Motiv 12: 239-260, 1981.
43. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, et al: Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45: 1150-1159, 2013.
44. Hobert O: Gene regulation by transcription factors and microRNAs. Science 319: 1785-1786, 2008.
45. Nilsen TW: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23: 243-249, 2007.
46. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I and Cairns MJ: Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17: 1156-1168, 2008.
47. Zhang F, Xu Y, Shugart YY, Yue W, Qi G, Yuan G, Cheng Z, Yao J, Wang J, Wang G, et al: Converging evidence implicates the abnormal microRNA system in schizophrenia. Schizophr Bull 41: 728-735, 2015.
48. Murphy KC, Jones LA and Owen MJ: High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56: 940-945, 1999.
49. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA and Cairns MJ: Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15: 1176-1189, 2010.
50. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I and Cairns MJ: Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17: 1156-1168, 2008.
51. Feng J, Sun G, Yan J, Noltner K, Li W, Buzin CH, Longmate J, Heston LL, Rossi J and Sommer SS: Evidence for X-chromosomal schizophrenia associated with microRNA alterations. PLoS One 4: e6121, 2009.
52. Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I, et al: Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2: e873, 2007.
53. Juhila J, Sipilä T, Icay K, Nicorici D, Ellonen P, Kallio A, Korpelainen E, Greco D and Hovatta I: MicroRNA expression profiling reveals miRNA families regulating specific biological pathways in mouse frontal cortex and hippocampus. PLoS One 6: e21495, 2011.
54. Rinaldi A, Vincenti S, De Vito F, Bozzoni I, Oliverio A, Presutti C, Fragapane P and Mele A: Stress induces region specific alterations in microRNAs expression in mice. Behav Brain Res 208: 265-269, 2010.
55. McLoughlin HS, Fineberg SK, Ghosh LL, Tecedor L and Davidson BL: Dicer is required for proliferation, viability, migration and differentiation in corticoneurogenesis. Neuroscience 223: 285-295, 2012.
56. Nigro A, Menon R, Bergamaschi A, Clovis YM, Baldi A, Ehrmann M, Comi G, De Pietri Tonelli D, Farina C, Martino G and Muzio L: MiR-30e and miR-181d control radial glia cell proliferation via HtrA1 modulation. Cell Death Dis 3: e360, 2012.
57. Xu Y, Liu H, Li F, Sun N, Ren Y, Liu Z, Cao X, Wang Y, Liu P and Zhang K: A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J Affect Disord 127: 332-336, 2010.